Halozyme Therapeutics, Inc. (HALO) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Analysis Summary
Halozyme Therapeutics, Inc. reported revenue of $1.40B in the most recent fiscal year, growing at a 5-year CAGR of 39.2%. Net income reached $316.9M, with a 19.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 78.2%, operating margin 56.8%, net margin 24.9%. Free cash flow grew at 64.8% CAGR over 5 years.
Balance sheet quality for HALO: current ratio of 4.7, net debt of $2.00B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $644.6M represents 203% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $108.44 |
| Market Cap | $12.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 30.18 |
| Price / Book | 86.81 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 78.18% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
Financial Health
| Debt / Equity | 14.95 |
| Current Ratio | 2.71 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| HSIC | Henry Schein, Inc. | $9.9B | 25.08 | 3.12 | 12.4% |
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| GRFS | Grifols, S.A. | $6.5B | 14.21 | 1.17 | |
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price Performance
| 1 month | +3.38% |
| 3 months | +58.19% |
| Year-to-date | +61.13% |
| 1 year | +43.04% |
| 3 years | +177.27% |
52-Week Range
| 52-week High | $111.15 |
| 52-week Low | $61.23 |
| Avg Volume (90d) | 1.9M |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks